Format of bispecific antibodies (BsAbs)-Hetero heavy chain, Common light chain

SOCAIL MEDIA

Since an IgG antibody has two antigen-binding fragments (Fab) both of which link to an Fc region, there had long been a concept of an asymmetric bispecific IgG antibody capable of binding to two different antigens or epitopes. The asymmetric reengineering technology immunoglobulin (ART-Ig) is a humanized asymmetric bispecific IgG antibody. An asymmetric bispecific IgG antibody typically has 2 kinds of heavy chain and 2 kinds of light chain. If the 4 chains were simultaneously expressed in a recombinant cell to produce the desired asymmetric bispecific IgG antibody, as many as 9 kinds of unwanted byproduct IgG molecules would also be assembled and secreted. A method of reducing the byproduct IgG molecules using a common light chain in the asymmetric bispecific IgG antibody and also by introducing “knobs-into-holes” mutations in its Fc region to prioritize a specific hetero-dimerization of the heavy chains.

Formats of bispecific antibodies (BsAbs)

Many formats have been developed for BsAb generation as listed in the following table.

Format	Description	Example BsAb	Trademark	Company
tandem VHH	Tandem VHH fragment-based BsAb	N/A
tandem scFv	Tandem ScFv fragment-based BsAb	AMG330	BiTE^TM	Amgen
Dual-affinity re-targeting antibody	Tandem domain-exchanged Fv (can also be used to fuse with Fc domain to create whole Abs)	Flotetuzumab	DART^TM	Macrogenics
Diabody	dimer of single-chain Fv (scFv) fragment	vixtimotamab	ReSTORE^TM	Amphivena Therapeutics
(scFv)2-Fab	a Fab domain and two scFv domains bind	A-337	ITab^TM	Generon/EVIVE Biotech
Rat–mouse hybrid IgG	Full-size IgG-like half antibodies from two different species	Catumaxomab	Triomab^TM	Trion Pharma
Hetero heavy chain, Common light chain	Hetero heavy chain, Common light chain	Emicizumab	ART-Ig^TM	Genentech/ Chugai/Roche
Controlled Fab arm exchange	Recombin the parental half antibodies	JNJ-64007957	Duobody^TM	Genmab/ Janssen
Hetero H, forced HL IgG1	KIH technology for heterodimerization of 2 distinct H chains, replacing the native disulfide bond in one of the CH1-CL interfaces with an engineered disulfide bond to enhance the cognate of H and L paring	MEDI5752	DuetMab^TM	MedImmune/ AstraZeneca
cH IgG1	Identical heavy chains; 2 different light chains: one kappa (κ) and one lambda (λ)	NI-1701	κλ body^TM	Novimmune SA
Hetero H, CrossMab	KIH technology; domain crossover of immunoglobulin domains in the Fab region	Vanucizumab	CrossMab^TM	Roche
scFv-Fab IgG	Fab-Fc; ScFv-Fc	Vibecotamab; M802	Xmab^TM (the engineered Fc to enhance the generation of heterodimeric Fc); YBODY^TM	Xencor/Amgen; YZYBio
VH1-VH2-CH1-Fc1(G1) x VL2-VL1-CL-Fc2(G1)	2 binding motif in one half antibody	SAR440234	CODV-Ig^TM	Sanofi
VL1-CL1-VH2-CH2-Fc x VH1-CH1 x VL2-CL2	2 binding motif in one half antibody	EMB-01	FIT-Ig^TM	EPIMAB BIOTHERAPEUTICS
VH-1-TCR Cα x VL-1-TCR Cβ; VH-2-CH-2-Fc x VL-2-CL-2	KIH technology; TCR Cα/Cβ is used to substitute the CH1 and CL domain in one arm		WuXibody^TM	WuXi Biologics
C-terminal linker of Fc	Link the other molecules at the C-terminal of Fc	APVO442	ADAPTIR-FLEX^TM	Aptevo Therapeutics
Fc antigen binding site	2 natural binding sites; 2 additional binding sites in the Fc loop	FS118	mAb²	F-star Therapeutics